BMS-817399

Cat. No.: HY-15546

CAS No.: 1202400-18-7

Molecular Formula: $C_{23}H_{36}ClN_3O_4$

Molecular Weight: 454

Target: CCR

Pathway: GPCR/G Protein; Immunology/Inflammation

Storage:

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (220.26 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.2026 mL	11.0132 mL	22.0264 mL
	5 mM	0.4405 mL	2.2026 mL	4.4053 mL
	10 mM	0.2203 mL	1.1013 mL	2.2026 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.51 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (5.51 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.51 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

BMS-817399 is a potent, selective, and orally bioavailable CCR1 antagonist. BMS-817399 exhibits CCR1 binding affinity and chemotaxis inhibition potencies of 1 and 6 nM (IC_{50}), respectively. BMS-817399 can be used for the research of rheumatoid arthritis[1].

IC_{50} & Target

CCR1
1 nM (IC_{50})

In Vitro

In addition to MIP-1α (CCL3), BMS-817399 potently inhibits chemotaxis induced by other CCR1 ligands[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Santella JB 3rd, et al. Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. J Med Chem. 2014;57(18):7550-7564.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA